Trials / Not Yet Recruiting
Not Yet RecruitingNCT07131644
Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
A Randomized Controlled Trial Comparing Three Sirolimus Discontinuation Strategies in Patients With Kaposiform Hemangioendothelioma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sirolimus | Comparison of different sirolimus discontinuation strategies. |
Timeline
- Start date
- 2025-09-13
- Primary completion
- 2027-09-01
- Completion
- 2028-02-01
- First posted
- 2025-08-20
- Last updated
- 2025-09-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07131644. Inclusion in this directory is not an endorsement.